{'fraction_non_alphanumeric': 0.043204320432043204, 'fraction_numerical': 0.05310531053105311, 'mean_word_length': 4.731958762886598, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.

AIM
To analyze the clinical profile and outcomes of patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital.


METHODS
Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital.


RESULTS
189 patients (age 76.0 ± 9.4 years; CHA2DS2-VASc 4.1 ± 1.7; HAS-BLED 2.1 ± 0.9) were included. Rivaroxaban 20 mg was taken by 74.1% of patients. Among patients treated with rivaroxaban 20 and 15 mg, only 3.6 and 22.5%, respectively, received an inadequate dose. After 26.6 ± 11.6 months of treatment, annual discontinuation rate was 1%. Rates of stroke, major bleeding and intracranial hemorrhage were 0.45, 0.22 and 0.22 events/100 patient years, respectively.


CONCLUSION
In our practice of regional hospital, rates of discontinuation, thromboembolic and bleeding outcomes are low.